Hematology Updates: Mim8, Breyanzi, Axi-Cel, Ziftomenib, CAR-T, DLBCL, MCL, Blinatumomab, Avapritinib — and more
This week’s edition highlights CAR-T therapy advancements, novel targeted treatments, and cutting-edge immunotherapies shaping the future of hematology.
In this episode of Hematology Updates, we delve into the latest breakthroughs in the field:
📌 Mim8 (Phase 3 FRONTIER3 trial) – 74.3% of pediatric patients had zero treated bleeds, and 98% of caregivers preferred Mim8 over previous therapies. Regulatory submissions expected in the United States and European Union.
📌 Breyanzi (TRANSCEND FL trial) – 97.1% overall response rate, 94.2% complete response rate in relapsed or refractory follicular lymphoma. Awaiting European Commission approval.
📌 Acalabrutinib, Venetoclax, Obinutuzumab in Mantle Cell Lymphoma – Complete response rates: 78% (relapsed/refractory), 81% (treatment-naïve), 75% (TP53-aberrant cases). Manageable safety profile.
📌 Polatuzumab-R-CHP vs. R-CHOP in DLBCL – 5-year PFS: 64.9% vs. 59.1%, 5-year OS: 82.3% vs. 79.5% in favor of Polatuzumab-R-CHP.
📌 Ziftomenib (KOMET-001 trial) – FDA submission planned for Q2 2025 after achieving complete remission endpoints in NPM1-mutant AML.
📌 UF-Kure19 CAR-T therapy – 80% CR rate, low toxicity (20% CRS, 10% neurotoxicity) in relapsed or refractory NHL.
📌 AJ1-11095 in Myelofibrosis – A first-in-class Type II JAK2 inhibitor being evaluated in Phase 1 for patients resistant to Type I inhibitors.
📌 Avapritinib in Systemic Mastocytosis – First-line OS: Not reached vs. 28.6 months (midostaurin), Second-line OS: Not reached vs. 20.3 months (best available therapy).
📌 Blinatumomab in ALL – Reinforces MRD-negative survival benefits, with ongoing trials to determine optimal sequencing strategies.
📌 Emavusertib in AML & MDS – Shows strong potential in combination with venetoclax or hypomethylating agents.
📌 Axi-Cel (ZUMA-5 trial, 5-year data) – 90% overall response rate, 75% complete response rate, 5-year OS: 83.4% in indolent non-Hodgkin lymphoma.
🔔 Stay Updated with LucidQuest!
🔔 Like, share, and subscribe to stay ahead of the latest in hematology research.
#LucidQuest #Hematology #CancerResearch #ClinicalTrials #Leukemia #Lymphoma #CART #Immunotherapy #FDAApproval #MedicalInnovation